O aumento do reflexo de sobressalto na presença de um estímulo que tenha sido previamente pareado a choques nas patas é tomado como índice de medo e nomeado sobressalto potencializado pelo medo (SPM). O congelamento, interrupção de todos os movimentos observáveis, exceto aqueles associados com a respiração, também tem sido utilizado como índice de medo em ratos. Um crescente número de evidências sugere o envolvimento de mecanismos dopaminérgicos em diferentes aspectos da memória afetiva, como sua formação, evocação e expressão. No entanto, resultados sobre como e por meio de quais receptores os mecanismos dopaminérgicos influenciam o medo têm sido inconsistentes. O presente estudo examina o envolvimento dos receptores dopaminérgicos na aquisição e na expressão do medo condicionado à luz. Para isso, foram analisados os efeitos do antagonista D1, SCH 23390, do agonista D1, SKF 38393, do antagonista D2, sulpirida, e do agonista D2, quimpirole, no SPM e no congelamento. A atividade motora dos animais também foi avaliada no teste do campo aberto. SCH 23390, SKF 38393, sulpirida e quimpirole, administrados antes do condicionamento, não produziram efeitos no SPM, mas SCH 23390 diminuiu o congelamento. As administrações de SCH 23390, SKF 38393 e sulpirida antes do teste também não produziram efeitos no SPM e no congelamento. Quimpirole, em doses que agem em receptores pré-sinápticos, causou uma redução significativa no SPM e no congelamento, quando administrado antes do teste. A ação das drogas não foi devida a efeitos não-específicos uma vez que elas não produziram efeitos no teste do campo aberto. Os resultados sugerem que mecanismos dopaminérgicos devem estar envolvidos tanto na aquisição, quanto na expressão do medo condicionado à luz. Receptores D1 pós-sinápticos parecem participar da aquisição do congelamento condicionado à luz-CS, mas não do SPM. Por outro lado, receptores D2 pré-sinápticos parecem estar envolvidos na expressão do medo condicionado à luz-CS. / The increase in the startle reflex in the presence of a stimulus that has been previously paired to footshock is taken as an index of fear and named fear potentiated startle (FPS). Freezing behavior, a cessation of all observable movements, except those associated with respiration, has also been used as an index of fear in rats. A growing body of evidence has suggested that dopaminergic mechanisms are implicated in different aspects of affective memory, namely its formation, expression or retrieval. However, the results of studies that have examined how, and through which receptors, dopaminergic mechanisms influence fear have been inconsistent. This work is aimed at examining the involvement of dopaminergic receptors in the acquisition and expression of conditioned fear to ligth-CS. We evaluated the effects of systemic administration of the D1 antagonist, SCH 23390, the D1 agonist, SKF 38393, the D2 antagonist, sulpiride, and the D2 agonist, quinpirole before and after conditioning on FPS and freezing. The motor activity of the animals was also evaluated in an open field test. SCH 23390, SKF 38393, sulpiride and quinpirole, injected before conditioning sessions, did not produce any effect on FPS, but SCH 23390 decreased freezing. Injections of SCH 23390, SKF 38393 and sulpiride before testing session did not produce any effect on FPS or freezing. Quinpirole, injected at doses acting at presynaptic level, caused significant reduction in FPS and freezing, when injected before testing. Drugs’ action was not due to nonspecific effects since they had no effect in the open field test. Our findings indicate that DA mechanisms are involved in the acquisition and expression of conditioned fear using light-CS. Dopaminergic mechanisms mediated by postsynaptic D1 receptors seem to be involved in the acquisition of conditioned freezing to light-CS, but not in FPS. On the other hand, dopaminergic mechanisms mediated by presynaptic D2 receptors seem to be involved in the expression of conditioned fear to light-CS.

O aumento do reflexo de sobressalto na presença de um estímulo que tenha sido previamente pareado a choques nas patas é tomado como índice de medo e nomeado sobressalto potencializado pelo medo (SPM). O congelamento, interrupção de todos os movimentos observáveis, exceto aqueles associados com a respiração, também tem sido utilizado como índice de medo em ratos. Um crescente número de evidências sugere o envolvimento de mecanismos dopaminérgicos em diferentes aspectos da memória afetiva, como sua formação, evocação e expressão. No entanto, resultados sobre como e por meio de quais receptores os mecanismos dopaminérgicos influenciam o medo têm sido inconsistentes. O presente estudo examina o envolvimento dos receptores dopaminérgicos na aquisição e na expressão do medo condicionado à luz. Para isso, foram analisados os efeitos do antagonista D1, SCH 23390, do agonista D1, SKF 38393, do antagonista D2, sulpirida, e do agonista D2, quimpirole, no SPM e no congelamento. A atividade motora dos animais também foi avaliada no teste do campo aberto. SCH 23390, SKF 38393, sulpirida e quimpirole, administrados antes do condicionamento, não produziram efeitos no SPM, mas SCH 23390 diminuiu o congelamento. As administrações de SCH 23390, SKF 38393 e sulpirida antes do teste também não produziram efeitos no SPM e no congelamento. Quimpirole, em doses que agem em receptores pré-sinápticos, causou uma redução significativa no SPM e no congelamento, quando administrado antes do teste. A ação das drogas não foi devida a efeitos não-específicos uma vez que elas não produziram efeitos no teste do campo aberto. Os resultados sugerem que mecanismos dopaminérgicos devem estar envolvidos tanto na aquisição, quanto na expressão do medo condicionado à luz. Receptores D1 pós-sinápticos parecem participar da aquisição do congelamento condicionado à luz-CS, mas não do SPM. Por outro lado, receptores D2 pré-sinápticos parecem estar envolvidos na expressão do medo condicionado à luz-CS. / The increase in the startle reflex in the presence of a stimulus that has been previously paired to footshock is taken as an index of fear and named fear potentiated startle (FPS). Freezing behavior, a cessation of all observable movements, except those associated with respiration, has also been used as an index of fear in rats. A growing body of evidence has suggested that dopaminergic mechanisms are implicated in different aspects of affective memory, namely its formation, expression or retrieval. However, the results of studies that have examined how, and through which receptors, dopaminergic mechanisms influence fear have been inconsistent. This work is aimed at examining the involvement of dopaminergic receptors in the acquisition and expression of conditioned fear to ligth-CS. We evaluated the effects of systemic administration of the D1 antagonist, SCH 23390, the D1 agonist, SKF 38393, the D2 antagonist, sulpiride, and the D2 agonist, quinpirole before and after conditioning on FPS and freezing. The motor activity of the animals was also evaluated in an open field test. SCH 23390, SKF 38393, sulpiride and quinpirole, injected before conditioning sessions, did not produce any effect on FPS, but SCH 23390 decreased freezing. Injections of SCH 23390, SKF 38393 and sulpiride before testing session did not produce any effect on FPS or freezing. Quinpirole, injected at doses acting at presynaptic level, caused significant reduction in FPS and freezing, when injected before testing. Drugs’ action was not due to nonspecific effects since they had no effect in the open field test. Our findings indicate that DA mechanisms are involved in the acquisition and expression of conditioned fear using light-CS. Dopaminergic mechanisms mediated by postsynaptic D1 receptors seem to be involved in the acquisition of conditioned freezing to light-CS, but not in FPS. On the other hand, dopaminergic mechanisms mediated by presynaptic D2 receptors seem to be involved in the expression of conditioned fear to light-CS.

The influence of central dopaminergic fibers on drug-induced oral activity in rats has not been well studied. Rats were treated 3 days after birth with bilateral intracerebroventricular 6-hydroxydopamine (6-OHDA; 134 ωg total, base form) to destroy dopaminergic fibers in the brain. Control rats received vehicle by the same route. At about 10 weeks of age, a challenge dose of the dopamine D2 receptor antagonist, spiperone (40 ωg/kg, IP), produced an 8-fold increase in the number of oral movements during a 60-minute observation period, vs. the control group. SKF 38393 (3.0 mg/kg, IP), a D1 agonist, produced the same number of oral movements as spiperone in the 6-OHDA group, representing a 2.4-fold increase over the controls. The Bmax and Kd for both D1 and D2 receptors was not changed in rat striatum by neonatal 6-OHDA treatment, even though dopamine content was reduced by 96%. These findings demonstrate that oral activity in rats can be greatly altered, even when there is no change in absolute numbers of D1 and D2 receptors and no change in the ratio of D1:D2 receptors.

Neonatal 6-hydroxydopamine (6-OHDA) treatment of rats is associated with supersensitization of the dopamine (DA) D1 agonist induction of stereotyped and locomotor behaviors. The present study was conducted to determine whether ontogenetic treatments of these rats with the DA D1 receptor agonist, SKF 38393, would produce a maximal DA D1 receptor supersensitivity, as measured by locomotor behavior in adulthood. Rat pups were treated daily with SKF 38393-HCl (3.0 mg/kg per day, i.p.) or saline vehicle for 28 consecutive days from birth. These animals were additionally treated at 3 days after birth with 6-OHDA-HBr (100 μg, in each lateral ventricle, salt form) or its vehicle. Between 6 and 9 weeks locomotor activity or stereotyped behaviors were observed after weekly challenge doses of SKF 38393-HCl (3.0 mg/kg, i.p.). In the neonatal 6-OHDA group, successive SKF 38393 treatments produced progressively greater locomotor activity. In the group of rats treated during postnatal ontogeny with both 6-OHDA and SKF 38393 daily treatments, the first adult challenge dose of SKF 38393 produced an enhanced locomotor response, greater than that seen in other groups (P < 0.01). Subsequent SKF 38393 treatments of this group produced increasingly greater locomotor responses. SKF 38393-induced stereotyped behavioral effects were greater in the 6-OHDA-lesioned groups, whether or not SKF 38393 was administered ontogenetically. Profound reductions (> 99%) of DA and its metabolites were found in the striatum of neonatal 6-OHDA treated rats, regardless of whether SKF 38393 was co-administered ontogenetically. A marked elevation in striatal 5-HT (> 50%) accompanied the DA depletion in the striatum. These findings indicate that neonatal 6-OHDA treatment produces the expected destruction of striatal DA fibers with associated sprouting of 5-HT fibers, while repeated ontogenetic treatments of these rats with a D1 agonist produces partial sensitization of the DA D1 receptors in adulthood.

Our laboratories have been investigating the reactivity of central dopamine D1 and D2/D3 receptors by their corresponding dopamine agonists (SKF-38393 and quinpirole), during development and aging in rats. By evaluating the number of oral movements (a parameter for D1 receptor activation after SKF-38393) and the number of yawns (as a parameter for D3 activation after quinpirole), we demonstrated that not only was there a dose-response activity for both drugs in the two parameters tested, but that the D3 activity was enhanced with the rats' development and aging, due to life-long persisting D3 supersensitivity. In the present study we checked whether D2 and D1 receptors were also sensitized at old age, by measuring behavioral parameters characteristic to D2 (locomotor activity and rearings) and to D1 (grooming time). In the long-term study, male Wistar rats were challenged for 18 months with increasing doses of either SKF-38393, quinpirole or saline. At the age of 19 months they were given a single injection of either drug or saline. In the short-term study, male and female rats were given four single injections of either SKF-38393, quinpirole or saline, with one week intervals, and locomotor time and number of rearings recorded. Long-term quinpirole was found to induce supersensitivity of the D2 receptor complex, demonstrated by both enhanced locomotor time and rearing behavior, while long-term SKF-38393 treatment activated the D1 receptors, as evaluated by grooming time. Short-term quinpirole enhanced supersensitivity of the D2 receptors only in female rats, as assessed by increasing both locomotor time and rearing behavior, reiterating previous results on sex-dependent monoaminergic reactivity.

Male and Female newborn rats were primed with either quinpirole 0.05 mg/kg IP or SKF-38393 0.1 mg/kg IP on days 1-11, 12-22 and 23-33 of their lives. When the rats reached the age of 13 weeks, they were placed on metal rods in an activity avoidance chamber, and light and electric current of 30V/0.8 mA were used on them as conditioning stimuli. Avoidance of the electric shock was considered a positive conditioned reaction. Training and memorizing the conditioned avoidance reflex consisted of a series of ten trials, 60 seconds apart, once a week for ten weeks. The mean number of positive responses after quinpirole was more profound in all priming intervals tested, as compared to SKF-38393, and was higher as the priming started later in life. Significantly higher scores were obtained by the female rats primed with quinpirole, as compared to the male rats primed with the same drug. These differences were much weaker with SKF-38393. These findings confirm that the central D2 receptor system is involved in learn ing and memorizing of Conditioned Avoidance Reflex much more than the D1 receptors do, and that female rats are more sensitive and retentive to this reflex.

Repeated treatments with a dopamine (DA) D2 receptor agonist result in the induction of DA D2 receptor supersensitivity, as evidenced by enhanced behavioral responses to subsequent D2 agonist treatments - a phenomenon known as priming of receptors. Priming of D2 receptors has been well-studied in otherwise intact (non-lesioned) rats. In contrast to D2 priming, repeated treatments with a DA D1 agonist are unable to prime D1 receptors unless nigrostriatal DA fibers are largely destroyed in early postnatal ontogeny. In order to determine if D2 receptors could be primed in rats in which nigrostriatal DA fibers were largely destroyed in early postnatal ontogeny, rats were (a) lesioned at 3 days after birth with 6-hydroxydopamine (67 μg in each lateral ventricle; desipramine, 20 mg/kg IP, 1 h; 6-OHDA), (b) treated daily for the first 28 days after birth with the D2 agonist quinpirole HCl (3.0 mg/kg IP), and (c) observed in adulthood for both quinpirole-induced and SKF 38393- (D1 agonist-) induced locomotor activity and stereotyped activities. In 6-OHDA-lesioned rats in which endogenous striatal DA was reduced by 99%, quinpirole did not produce enhanced locomotor or stereotyped activities. However, SKF 38393 produced increased locomotor and stereotyped activities even after the first dose of SKF 38393. These findings demonstrate that D2 receptors are not primed by ontogenetic quinpirole treatments of neonatally 6-OHDA-lesioned rats, although D2 agonist treatments do at least partially prime D1 receptors in 6-OHDA-lesioned rats.

Enhanced oral activity is induced in neonatal 6-hydroxydopamine- (6-OHDA-) lesioned rats by systemic administration of the dopamine (DA) D1 receptor agonist SKF 38393 and serotonin (5-HT) 5-HT2A,2C agonist m-chlorophenylpiperazine (m-CPP). The DA D1 receptor antagonist SCH 23390 effectively attenuates the effect of SKF 38393 but not m-CPP. The 5-HT2antagonist mianserin attenuates the effects of both m-CPP and SKF 38393, suggesting that DA agonist effects are mediated by 5-HT neurochemical systems. To test whether DA and 5-HT agonist effects and interactions might occur within the neostriatum, rats were implanted with permanent injection cannulae, with tips in the ventral striatum. One group of rats was lesioned at 3 days after birth with 6-OHDA HBr (100 μg salt form, in each lateral ventricle; desipramine HCl pretreatment, 20 mg/kg IP, base form, 1 h), while controls received the vehicle in place of 6-OHDA. Cannulae were implanted when rats weighed 200-250 g. During a 1-h observation session SKF 38393 (5 nmol per side) produced 74.3±19.2 oral movements in intact rats and 310.7±97.0 oral movements in 6-OHDA-lesioned rats. m-CPP (10 nmol per side) produced 72.6±15.1 and 274.5±65.0 oral movements in these respective groups. These responses were several-fold greater than the 25.3±7.3 and 41.8±9.5 oral movements in the same groups after saline (0.5 μl per side) (P<0.05). Mianserin (6 nmol per side) alone had no effect on oral activity but attenuated responses to both SKF 38393 and m-CPP in intact and 6-OHDA-lesioned rats. These findings demonstrate that enhanced oral activity responses are produced by intrastriatal SKF 38393 and m-CPP in neonatal 6-OHDA-lesioned rats. Also, when the 5-HT2 receptor antagonist mianserin was administered intrastriatally, induction of oral activity by the DA D1 agonist SKF 38393 was attenuated. These findings indicate that ventral striatum represents at least one brain focus at which DA and 5-HT systems interact to modulate oral activity in rats.

Neonatal 6-hydroxydopamine (6-OHDA) treatment of rats is associated with concurrent supersensitization of dopamine (DA) D1 and serotonin 5-HT1C receptors, for agonist-induced oral activity. The present study was conducted to determine if graded reduction of striatal DA content and/or graded elevation of striatal 5-HT content by 6-OHDA would alter sensitivity of either receptor type, and thereby influence oral activity responses to DA and 5-HT agonists. At 3 days after birth, groups of rats were pretreated with desipramine (20 mg/kg i.p.), 1 h before administration of a range of doses of 6-OHDA HBr (15, 30, 60, 100, 150 and 200 μg, i.c.v., salt form; half in each lateral ventricle) or the vehicle, saline (0.85%)-ascorbic acid (0.1%). Between 2 and 4 months, a series of challenge doses of SKF 38393 HCl (0.30 to 3.0 mg/kg i.p.) and m-chlorophenylpiperazine 2HCl (0.30 to 6.0 mg/kg i.p.; m-CPP 2HCl) were administered to each group of rats and oral activity was observed. Oral activity was determined for 1 min every 10 min during a 60-min period, starting 10 min after injection of agonist or vehicle. SKF 38393 dose-response curves demonstrated enhanced oral activity responses in rats lesioned neonatally with 150 or 200 μg of 6-OHDA. m-CPP dose-response curves demonstrated enhanced oral activity responses in these 2 groups of rats, as well as those lesioned neonatally with 100 μg of 6-OHDA. Striatal DA content was reduced by > 97% in these 3 groups of rats. Striatal 5-HT content was elevated by > 80% in rats treated neonatally with 150- or 200-μg doses of 6-OHDA, and by 50% in rats treated neonatally with the 100-μg dose of 6-OHDA. Lower doses of 6-OHDA produced less of an effect on striatal DA and 5-HT content. Regression analysis determined that both SKF 38393- and m-CPP-induced oral activities were most closely correlated with the magnitude of change in striatal content of DA. These findings demonstrate that 5-HT agonist responses can be enhanced when DA agonist responses are not enhanced. Also, in neonatal 6-OHDA-lesioned rats the extent of DA depletion vs. the extent of 5-HT elevation seems to be a critical factor in the enhanced behavioral effects of DA and 5-HT agonists.

l-Prolyl-l-leucyl-glycinamide (MIF-1) is known to attenuate apomorphine-induced stereotypies in adult rats that are lesioned as neonates with 6-hydroxydopamine (6-OHDA). To test whether MIF-1 would affect dopamine (DA) agonist-induced and serotonin (5-HT) agonist-induced oral activity, both intact and neonatal 6-OHDA-treated rats were studied. Rats at 3 days from birth were injected with desipramine (20 mg/kg, IP), 1 h before 6-OHDA HBr (100 μg, salt form, in each lateral ventricle) or its vehicle, saline-ascorbic acid (0.1%). At approximately 6 months rats were treated with MIF-1 (0.1, 1.0, or 10.0 mg/kg, IP), 10 min before SKF 39393 HCl (1.0 mg/kg, IP) or m-chlorophenylpiperazine 2HCl (m-CPP 2HCl; 0.5 mg/kg, IP), DA D1 and 5-HT1C,2 receptor agonists, respectively. Although both agonists increased oral activity in control and neonatal 6-OHDA-treated rats, MIF-1 did not modify the response. In rats that received either of the three doses of MIF-1 for 21 consecutive days, there was still no observed effect of MIF-1 on the oral response of control and 6-OHDA-lesioned rats to SKF 38393 and m-CPP. These findings indicate that MIF-1 does not modify the oral activity response of supersensitized D1 and 5-HT1C receptors in adult rats that are lesioned neonatally with 6-OHDA.